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ABSTRACT
Here we show that c17orf42, hereafter TEFM (tran-
scription elongation factor of mitochondria), makes
a critical contribution to mitochondrial transcription.
Inactivation of TEFM in cells by RNA interference
results in respiratory incompetence owing to
decreased levels of H- and L-strand promoter-distal
mitochondrial transcripts. Affinity purification of
TEFM from human mitochondria yielded a complex
comprising mitochondrial transcripts, mitochondrial
RNA polymerase (POLRMT), pentatricopeptide
repeat domain 3 protein (PTCD3), and a putative
DEAD-box RNA helicase, DHX30. After RNase treat-
ment only POLRMT remained associated with
TEFM, and in human cultured cells TEFM formed
foci coincident with newly synthesized mitochon-
drial RNA. Based on deletion mutants, TEFM inter-
acts with the catalytic region of POLRMT, and
in vitro TEFM enhanced POLRMT processivity on
ss- and dsDNA templates. TEFM contains two HhH
motifs and a Ribonuclease H fold, similar to the
nuclear transcription elongation regulator Spt6.
These findings lead us to propose that TEFM is a
mitochondrial transcription elongation factor.
INTRODUCTION
Mitochondria supply the bulk of the cell’s energy via the
process of oxidative phosphorylation (OXPHOS).
Although the majority of OXPHOS components are
encoded in the nuclear genome, 13 subunits of the
OXPHOS machinery are the products of a small, circular
genome in mammalian mitochondria. Human mitochon-
drial DNA (mtDNA) is dependent on the nucleus for all
the proteins involved in its maintenance and expression.
Recent years havewitnessed signiﬁcant progress towards
compiling a full list of mammalian mitochondrial proteins
thanks largely to advances in high-throughput methods
of tandem mass spectrometry (1–3) and comparative
genomics (4). However, to date only half of the estimated
1500 mitochondrial proteins have been identiﬁed and
current catalogues inevitably include false positives (2,5).
Moreover, functional assignment of a protein on the basis
of sequence homology has limited sensitivity and reliabil-
ity, as some mitochondrial enzymes differ structurally and
functionally from the homologous prokaryotic or eukary-
otic gene. For example, human mitochondrial RNase P
(mtRNase P), a tRNA processing enzyme, consists of
three subunits that do not share any signiﬁcant homology
with other RNase Ps. Human mtRNase P lacks a
catalytic RNA component that is present in all other
known RNase P enzymes and it appears to be a me ´ lange
of a tRNA methyltransferase, a short-chain dehydrogen-
ase/reductase-family member, and a protein of unknown
function and evolutionary origin (6). Two of the three
subunits of mtRNase P, the tRNA methyltransferase and
short-chain dehydrogenase, had been assigned to the mito-
chondrial proteome (2), yet this was not enough to predict
their function in tRNA processing. Therefore, it is import-
ant to combine global analyses of the mitochondrial
proteome with more focused studies that characterize
mitochondrial proteins.
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transcription of the human mitochondrial genome
have been identiﬁed; they include a monomeric RNA
polymerase (POLRMT), and mitochondrial transcrip-
tion factors A (TFAM) and B2 (TFB2M), which collect-
ively form an effective in vitro transcription system (7).
In addition, three regulatory factors are known,
mitochondrial transcription termination factor 1
(mTERF1) (8), possible transcription initiation regulator
mTERF2 (9) and a negative regulator of mammalian
mtDNA transcription mTERF3, (10). One of the
subunits of human mitochondrial ribosomal, MRPL12,
has been reported to interact directly with POLRMT
and stimulate its activity in vitro (11). However, the list
of mitochondrial transcription factors is unlikely to
be complete, in particular, one would anticipate the exist-
ence of a mitochondrial transcription elongation factor
(TEF); ﬁrst because TEFs are key elements of the tran-
scription apparatus in other systems (12) and because
RNA synthesis of mammalian mitochondrial DNA
yields polycistronic transcripts (13). Transcription from
the heavy strand promoter in the major non-coding
region (NCR) of mtDNA (HSP1) gives rise to a
polycistronic transcript covering almost the entire
molecule, which is subsequently processed to yield two
rRNAs, 10 mRNAs and 14 tRNAs. Although the
L-strand transcript can be shorter, initiation of transcrip-
tion at the light strand promoter (LSP) must yield an 11kb
precursor RNA to include all the coding information of
the L-strand of mtDNA.
We began to study the human gene product of c17orf42
because it shares sequence homology with known:
(i) proteins involved in transcription in Pro- and
Eukaryota and (ii) Holliday junction resolvases (HJRs),
such as bacterial RuvC (14) and yeast mitochondrial
CCE1 (15) and YDC2 (16). Recombinant c17orf42
protein proved incapable of resolving four-way junctions
in vitro, and other experiments indicated a role in mito-
chondrial transcription elongation, hence we propose the
name TEF of mitochondria, TEFM.
MATERIALS AND METHODS
Plasmid construction
In order to construct pcDNA5-TEFM.HA used for the
immunoﬂuorescence localization of the TEFM protein
(Figures 1C and 6C), the cDNA encoding TEFM
(c17orf42) was modiﬁed by PCR to introduce the HA
epitope tag (YPYDVPDYA) to the C-terminus of the
ZFP and ﬂanked with unique KpnI (50) and XbaI (30)
restriction sites. The resulting fragment was cloned into
pcDNA5/FRT/TO (Invitrogen) using the above restric-
tion sites.
In order to construct pcDNA5-TEFM.STREP2, used
to generate an inducible human embryonic kidney
(HEK) cell line, two oligonucleotides encoding FLAG
and STREP2 epitope tags were annealed and cloned into
XbaI (50) and ApaI (30) restriction sites of pcDNA5/FRT/
TO (Invitrogen). The resulting plasmid was named
pcDNA5-FST2. Then the cDNA encoding TEFM was
modiﬁed by PCR to introduce unique KpnI (50) and
XbaI (30) and the resulting fragment was cloned into
pcDNA5-FST2 using the above restriction sites.
In order to construct pcDNA5-POLRMT.STREP2,
used to generate an inducible HEK cell line, the cDNA
encoding POLRMT was modiﬁed by PCR to introduce
ﬂanking BamHI (50) and XbaI (30) sites, after digestion the
resulting fragment was cloned into pcDNA5-FST2.
In order to construct pGEX-GST.TEFM the cDNA
encoding TEFM without the ﬁrst 32 amino acids was
ampliﬁed by PCR to introduce unique EcoRI (50) and
XhoI (30). The resulting product was cloned into the
above sites into pGEX-4T1 (GE Healthcare) in-frame
with the GST coding sequence.
The pcDNA3-POLRMT encoding the POLRMT of full
length was constructed by introducing NheI site (50) and
the MYC-epitope tag and EcoRI (30) into the POLRMT
cDNA by PCR and cloning the resulting product into the
above sites of pcDNA3.1( ) (Invitrogen).
The pcDNA3-POLTMT-MTS-786-1230 encoding the
60 amino acids-long mitochondrial targeting sequence
(MTS) of POLRMT and the C-terminal portion of the
protein (residues 786–1230) was cloned as follows:
Firstly, the cDNA of POLRMT encoding the MTS was
ampliﬁed by PCR to introduce XbaI sites on 50- and
30-ends and the resulting product was cloned into NheI
and XbaI sites of pcDNA3.1(–) (Invitrogen). Secondly,
the cDNA encoding residues 786–1230 was ampliﬁed by
PCR to introduce XbaI (50) and the MYC-epitope tag and
EcoRI (30). The resulting product was fused to the MTS
harbouring pcDNA3.1(–) using XbaI and EcoRI.
The pcDNA-POLRMT-1-801 encoding the ﬁrst 801
amino acids of POLRMT was constructed by introducing
NheI site (50) and the MYC-epitope tag and EcoRI (30)
into the POLRMT cDNA encoding resides 1–801 by PCR
and cloning the resulting product into the above sites of
pcDNA3.1( ) (Invitrogen).
Maintenance and transfection of mammalian cell lines
Human A549 adenocarcinoma and 143B osteosarcoma
(HOS) cells that are routinely used by us for immunoﬂuor-
escence localization of mitochondrial proteins and/or
siRNA gene silencing were cultured in DMEM containing
2mM L-glutamine (Invitrogen) with 10% FBS. For
immunoﬂuorescence experiments A549 cells were grown
in 6-well plates to 90–95% conﬂuence and transfected
with 0.5mg of plasmid DNA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Twelve hours after transfection the cells were trypsinized
and transferred onto coverslips placed in 60-mm culture
dishes.
For the siRNA experiments electroporations of 143B
cells were performed using Cell Line Nucleofector
(Lonza), buffer kit V (Lonza), dsRNA (100pmol) and
applying programme I-13. For 6-day siRNA experiments
the cells were split 2 days after the ﬁrst electroporation
and electroporated as above on day three.
Flp-In T-Rex
TM HEK 293T cells (Invitrogen) that
allows for generating stable, tetracycline inducible expres-
sion of transgenes by the FLP recombinase-mediated
Nucleic Acids Research, 2011,Vol.39, No. 10 4285integration was used to express of TEFM.STREP2. HEK
cells were grown in DMEM containing 2mM L-glutamine
(Invirtogen), 10% tetracycline free FCS (Autogen
Bioclear) supplemented with 100mg/ml Zeocin
(Invivogen) and 15mg/ml Blasticidin (Invitrogen).
Twenty-four hours prior to, transfection cells were split
to 10-cm plates and grown to 80–90% conﬂuence. HEK
cells were transfected according to the manufacturer’s in-
struction using Cell Line Nucleofector (Lonza), buffer kit
V (Lonza) applying programme A-23. The pcDNA5/
FRT/TO plasmid DNA encoding appriopriate
TEFM.STREP2 was puriﬁed by Qiaﬁlter MidiPrep Kit
(Qiagen). Twenty-four hours after the transfection the se-
lective antibiotics hygromycin (100mg/ml) and blasticidin
(15mg/ml) were added and the selective medium was
replaced every 3–4 days.
Immunoﬂuorescence
A549 cells were cultured in DMEM with 10% FBS as
above. For RNA labelling with BrU the medium was sup-
plemented with 2.5mM bromouridine (BrU, Sigma) for
30min prior to ﬁxation. To visualize mitochondria,
30min prior to ﬁxation the culture medium was replaced
with one containing 100nM MitoTracker Red CMXRos
(Invitrogen). Cells were then washed 3 times with PBS and
ﬁxed for 15min at room temperature using 3.7% formal-
dehyde 5% sucrose (w/v) solution in PBS. Fixed cells were
permeabilized with 1% Triton X-100 10% FBS solution in
PBS for 5min. They were then blocked for 1h with 10%
FBS solution in PBS. Cells were incubated with primary
antibodies for 1h in 10% FBS solution and subsequently
for 1h in the dark with secondary antibodies in 10% FBS
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Figure 1. In silico identiﬁcation and mitochondrial localization of TEFM. (A) Domain architecture of proteins homologous to TEFM. Green blocks
indicate the tandem helix-hairpin-helix domains (HhH, Pfam PF00633) found in transcription related and DNA binding proteins. The RuvC and YqgF
(Pfam PF03652) motifs (blue) exhibit the typical topology and structural elements of the RNase H fold. S1 domain (red) typically binds RNA whereas the
SH2domain(grey)isfoundinmanyproteinsinvolvedinsignaltransductionandisresponsibleforprotein–proteininteraction.SAPmotif(PfamPF02037,
yellow)represents aputative DNAbinding domainfoundin adiversenumberofproteinsinvolved inchromosomal organization (40).TheMTS presentin
TEFM is indicated in orange. See Supplementary Data for further details. (B) Sub-cellular location of TEFM. The HOS cells were fractionated into
fraction containing unbroken cells and cell debris (‘D’, lane 2), cytosol (‘C’, lane 3) and mitochondria (‘M’, lane 4) as described ‘Materials and Methods’
section.TheproteinfractionswereanalysedbywesternblottingusingantibodiestoendogenousTEFM.ThelocationofTEFMwascomparedwiththatof
the following marker proteins: TFAM (mitochondrial matrix), TOM22 (mitochondrial outer membrane), GAPDH (cytosol). (C) The intra-cellular
localization of the HA-tagged variant of TEFM (green) by immunoﬂuorescence, in human A549 cells, as described in ‘Materials and Methods’
section. Mitochondria were stained with MitoTracker Red CMXRos (red); the nucleus was stained with DAPI (blue). Yellow signal on digitally
overlaid pictures indicated that TEFM has the same cellular distribution as mitochondria.
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tion in 50nM DAPI solution in PBS for 1min and
washed. The whole procedure was performed at room
temperature and the cells were washed 3 times with PBS
between each step. After the ﬁnal washing the coverslips
were mounted on Superfrost slides in Mowiol medium and
left in the dark for 4h at room temperature and then over-
night at 4 C; immunoﬂuorescence was viewed using a
Zeiss LSM 510 META confocal microscope.
The following primary antibodies were used (dilution in
brackets): rat anti-HA IgG (Roche, 1:200); mouse
anti-DNA IgM (Progen, 1:100); mouse anti-BrdU IgG
(Roche, 1:50). Secondary antibodies: Cy5-conjugated
anti-rat IgG (Abcam, 1:200); FITC-conjugated anti-rat
IgG (Abcam, 1:200); FITC-conjugated anti-mouse IgM
(Sigma, 1:200); TRITC-conjugated anti-mouse IgG
(Sigma, 1:200).
Western blotting
For immunoblot analysis equal amounts of proteins cor-
responding to total cell lysates or protein fractions were
subjected to SDS–PAGE or blue native/SDS–PAGE 2D
electrophoresis, semi-dry transferred to nitrocellulose
membranes, blocked in 5% non-fat milk (Marvel) in
PBS for 1h and incubated with speciﬁc primary antibodies
in 5% non-fat milk in PBS for 1h or overnight. The blots
were further incubated with HRP-conjugated secondary
antibodies in 5% non-fat milk in PBS for 1h and
visualized using ECL (Amersham).
The primary antibodies used were: mouse anti-FLAG
IgG (Sigma, 1:5000), rabbit anti-Myc (Abcam, 1:1000),
rabbit anti-POLRMT IgG (1:1000, Abcam), rabbit
anti-PTCD3 IgG (1:1000, Santa Cruz Biotechnology),
rabbit anti-DHX30 IgG (1:1000, Abcam), rabbit anti-
VDAC-1 IgG (1:1000, Abcam), mouse anti-Cox2 IgG
(1:5000, Abcam), rabbit anti-TFAM IgG (kindly
provided by Dr D. Kang, Kyushu University, Japan,
1:4000), goat anti-TFB2M (1:1000, Abcam), mouse anti-
TOM22 IgG (Abcam, 1:5000), mouse anti-GAPDH IgG
(Abcam, 1:10000), rabbit anti-c17orf42 (Sigma, 1:1000),
mouse anti-Complex I subunit NDUFB8 (MitoSciences,
1:2000), mouse anti-Complex II subunit 30kDa
(MitoSciences, 1:1000), mouse anti-Complex III subunit
Core 2 (MitoSciences, 1:1000), rabbit anti-Complex V
subunit G (prepared by the ATP synthase group in the
MRC Mitochondrial Biology Unit, 1:1000).
Secondary antibodies were: anti-rat IgG-HRP (Sant
Cruz Biotechnology, 1:2000), anti-rabbit IgG-HRP
(Promega, 1:2000), anti-mouse IgG-HRP (Promega,
1:2000), anti-goat IgG-HRP (Sigma, 1:1000).
Oligonucleotides for TEFM siRNA
dsRNAs (iGene Therapeutics) for the TEFM siRNA
experiments were:
Oligo 1 forward: UCCAAAGACUGGACGGGAAAAA
AGA
Oligo 1 reverse: AGGUUUCUGACCUGCCCUUUUU
UCU
Oligo 2 forward: GGACUAGUGGAAAAGAGCUAG
UGAA
Oligo 2 reverse: CCUGAUCACCUUUUCUCGAUCAC
UU
The control RNA oligonucleotides to GFPmax were from
the siRNA Test Kit (Lonza)
Measurement of mitochondrial respiration
Human 143B cells were seeded at 1.5–2 10
4 cells/well in
200ml growth medium in XF 24-well cell culture
microplates (Seahorse Bioscience, Billerica, MA, USA)
and incubated at 37 Ci n5 %C O 2 for 36–40h. One hour
beforetheassaygrowthmediumwasremovedandreplaced
with assay medium (low buffered DMEM, 10mM L-glu-
tamine, 1mM sodium pyruvate, 2mM glucose), with
one rinse with assay medium, and left to stabilize for 1h
in a 37 C non-CO2 incubator. Analysis was performed in
quadruplicates using XF24 Extracellular Flux Analyzer
(Seahorse Bioscience, Billerica, MA, USA). The wells
containing cells were sequentially injected with 20mM
2-deoxyglucose (2-DG) to inhibit glycolysis, 100nM
oligomycin to inhibit ATP-synthase, 500–1000nM
carbonylcyanide-4-triﬂuorometho-xyphenylhydrazone
(FCCP) to uncouple the respiratory chain, and 200nM
rotenone to inhibit complex I. Oxygen consumption rate
(OCR) was measured for each well every 5min before
and after each injection. Respiratory control ratio
(RCR=OCRFCCP/OCRoligomycin) was calculated for
each well each time using average of three OCR measure-
ments. Test compounds: 2-DG, oligomycin, FCCP and
rotenone were obtained from Sigma (St Louis, MO, USA).
RNA isolation and northern blotting
Total RNA from HOS cells was isolated using Trizol
(Invitrogen) according to the manufacturer’s instructions.
In order to analyse mitochondrial mRNAs and rRNAs in
northern blots, RNA was resolved on 1% agarose gels
containing 0.7M formaldehyde in 1  MOPS buffer,
transferred to a nylon membrane in 2  SSC and
hybridized with radioactively labelled PCR fragments cor-
responding to appropriate regions of mtDNA. In order to
analyse mitochondrial tRNAs in northern blots, RNA
was resolved on 5% UREA polyacrylamide gel in 1 
GTE buffer containing 90mM Tris base, 30mM
Taurine, 0.5mM EDTA and electrotransferred to a
nylon membrane in 0.5  TBE buffer. The blots were
hybridized with appropriate antisense mitochondrial
tRNAs produced by in vitro transcription using
MAXIscript T7 Kit (Ambion) in the presence of a-
32P
UTP (3000Ci/mmol, Perkin Elmer) according to the
manufacturer’s instructions.
Isolation of mitochondria
HEK cells were cultured in DMEM with 10%
tetracycline-free FBS (Autogen Bioclear). Expression of
TEFM.STREP2 was induced 24h after the last plating
by adding doxycycline to a ﬁnal concentration of
20ng/ml. Twenty-four hours after induction the cells
were harvested and mitochondria were prepared based
Nucleic Acids Research, 2011,Vol.39, No. 10 4287on a modiﬁed procedure adopted from (17) as follows.
The whole procedure was performed on ice or at 4 C.
Cells were detached by pipetting and pelleted by centrifu-
gation for 10min at 300 gmax, then washed twice with PBS
and the ﬁnal pellet was weighed to determine its volume
(assuming a density of 1.25g/ml). Cells were then resus-
pended in nine volumes of hypotonic buffer containing
20mM HEPES (pH 8.0), 5mM KCl, 1.5mM MgCl2
with 1mg/ml BSA, 2mM DTT, 0.2 PMSF and protease
inhibitors (Roche), incubated on ice for 10min and
homogenized with 10 strokes of a tight-ﬁtting 15ml glass
Dounce homogenizer (cell disruption was monitored by
microscopic examination). Next, two-third of total
volume of 2.5  MSH buffer [525mM mannitol, 175mM
sucrose, 20mM HEPES (pH 8.0), 5mM EDTA with
1mg/ml BSA, 2mM DTT, 0.2 PMSF and protease inhibi-
tor cocktail (Roche)] was immediately added and the
homogenate was centrifuged for 10min at 1600gmax. The
pellet was discarded and the supernatant was centrifuged
again. The pellet containing the cell debris and nuclei was
resuspended in 0.5ml of 1  MSH buffer [210mM
mannitol, 70mM sucrose, 20mM HEPES (pH 8.0),
2mM EDTA with 1mg/ml BSA, 2mM DTT, 0.2 PMSF
and protease inhibitors (Roche)] and stored in  20 C. The
cytoplasmic fraction was centrifuged for 10min at
8900gmax and a 0.5ml sample the supernatant containing
the cytosolic fraction was stored in  20 C. The pellet con-
taining the mitochondrial fraction was resuspended in 1 
MSH buffer supplemented with 10mM MgCl2 to a ﬁnal
protein concentration of 2mg/ml (assuming 10mg of
mitochondrial protein per 1g of cell pellet) and DNase I
(Sigma) was added to a ﬁnal concentration of 0.2mg/ml
(DNase I treatment removes contamination by residual
nuclear DNA and chromatin proteins). The sample was
rotated for 30min and the reaction was terminated by
adding EDTA to a ﬁnal concentration of 15mM. The
sample was washed three times with 5ml of MSH buffer
without BSA by centrifugation for 10min at 8900 gmax.
After washing, the pellet was suspended in 0.1–0.2 of
volume of MSH buffer without BSA, loaded onto a
sucrose gradient (see below) and centrifuged for 40min
at 117000gmax (33000rpm in a MLS50 rotor, Beckman
Coulter). The gradient was prepared by layering 1M and
1.5M sucrose solutions in fresh gradient buffer [10mM
HEPES (pH 7.8), 5mM EDTA, 2mM EDTA, 2mM
DTT] in polyallomer tubes (Beckman Coulter). After the
centrifugation, the interface was collected and four
volumes of gradient buffer were slowly added with
gentle vortexing. The sample was then centrifuged for
10min at 8900gmax, the supernatant discarded and the
mitochondria resuspended in MSH buffer without BSA.
Isolation of STREP2-tagged complexes from HEK cells
Mitochondria derived from HEK cells expressing the
TEFM.STREP2 transgene were isolated as described
above and resuspended to 8mg protein/ml in 40mM
HEPES (pH 7.6), 10mM EDTA, 4mM DTT, 0.4mM
PMSF, 300mM NaCl and protease inhibitors cocktail
(Roche). Next, the mitochondria were lysed by mixing
with an equal volume of 0.8% dodecylmaltoside (DDM)
in water, on a roller at 4 C for 30min. The lysate was
centrifuged at 1600gmax for 10min to remove insoluble
debris and the supernatant was load onto a gravity ﬂow
Strep-Tactin column (IBA) and the ﬂow-through
re-loaded twice. The column was washed sequentially
with ﬁve column volumes (CV) of washing buffer contain-
ing 20mM HEPES (pH 7.6), 1mM EDTA, 2mM DTT,
0.2mM PMSF, 150mM NaCl, 0.05% DDM, protease in-
hibitors (Roche) and eluted with six lots of 0.5 CV elution
buffer (washing buffer plus 5mM dethiobiotin).
Strep-Tactin puriﬁed proteins were separated by SDS–
PAGE, Coomassie-stained protein bands were excised
from gels and identiﬁed by mass spectrometry.
Mass spectrometry
Strep-Tactin puriﬁed proteins were separated by 4–12%
gradient SDS–PAGE (NuPage, Invitrogen).
Coomassie-stained protein bands were excised from gels
and digested by ‘in-gel’ cleavage (18) at 37 C overnight
with trypsin (Roche Diagnostic GmbH). Peptide
products were analysed in an ABI plus
MALDI-TOF-TOF Mass Spectrometer using a-cyano-4–
hydroxy-tans-cinnamic acid as the matrix. The mass
spectral data were analysed by Peaks to MASCOT
Tool and proteins were identiﬁed using MASCOT
database searching. The criteria for identiﬁcation of
proteins were a signiﬁcant PMF score, as deﬁned by
MASCOT (>70ppm), and at least two MS/MS peptide
matches.
Production of recombinant TEFM in E. coli
The BL21(DE3) Escherichia coli strain harbouring the
pGEX-GST.TEFM plasmid was grown at 37 C until
OD600=0.6 and induced with 50mM IPTG for 16h at
25 C. The pellet was resuspended in a buffer containing
20mM Tris–Cl (pH 8.0), 150mM NaCl and 1mM DTT
and sonicated for 3min (10s with 60s intervals, Misonix
3000 sonicator, output 6). Cell lysate was ﬁltered through
a 0.45mm syringe ﬁlter and run twice through a column
with 1ml Glutathione-Sepharose 4B (GE Healthcare).
The column-bound protein was eluted with ﬁve column
volumes of buffer containing 40mM Glutathione
(Sigma), 35mM NaOH, 20mM Tris–Cl (pH 8.0),
150mM NaCl and 1mM DTT. Peak fractions were sub-
jected to FPLC on a Supedex G200 column. The fractions
from the Supedex G200 column were assessed by SDS–
PAGE and the peak fractions as indicated on
Supplementary Figure S5 were concentrated using
Vivaspin 2 Centrifugal Concentrators (Sartorius stedim)
and stored at  80 C in a buffer containing 20mM Tris–
Cl (pH 8.0), 150mM NaCl, 1mM DTT and 20% glycerol.
In vitro RNA synthesis on ssDNA and dsDNA
The reactions were performed essentially as described by
(19) with the following modiﬁcations. The reaction
mixture of 20ml containing 200ng of single stranded
M13mp18 DNA (Amersham) or 1pmol of 30-tailed
dsDNA of various length, 10mM Tris–Cl, (pH 8.0),
20mM MgCl2, 1mM DTT, 100mg/ml BSA, 400mM
ATP, 150mM CTP, 150mM GTP, 10mM UTP
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UTP (3000Ci/mmol, Perkin Elmer), 4U of RNasin
(Promega), 0.35pmol of POLRMT (kindly provided by
Drs Gustafsson and Falkenberg, Karolinska Institutet,
Stockholm, Sweden) and indicated concentrations of
recombinant TEFM. The mixture was incubated for 1h
for the ssDNA template or indicated times for the 30-tailed
templates at 32 C. The samples were analysed on a 5%
UREA polyacrylamide gel in 1  GTE buffer containing
90mM Tris base, 30mM Taurine and 0.5mM EDTA.
The T7 RNA polymerase (T7RNAP) is used in the bac-
terial expression system based on the BL21 E. coli strain
that was employed to over express TEFM and hence
might have contaminated the recombinant TEFM prepar-
ations. In order to exclude a potential effect of the
presence of T7RNAP on the in vitro RNA synthesis on
ssDNA by POLRMT, we performed the reaction as
described above together with various concentrations of
T7RNAP (Fermentas) (Supplementary Figure S6).
The long 30-tailed dsDNA templates were constructed
according to our new procedure as follows: a 400bp
fragment containing the NCR region of human mtDNA
downstream from the LSP promoter lacking the conserved
sequence block II was ampliﬁed by PCR. The forward
primer used in the reaction contained an overhang of 15
uracils. After the PCR reaction the DNA product was
digested with the mixture of Uracil DNA glycosylase
(UDG) and the DNA glycosylase-lyase Endonuclease
VIII (USER Enzyme, New England Biolabs) and
agarose gel puriﬁed. The short 30-tailed dsDNA templates
of 20 or 100bp were constructed by annealing two com-
plementary oligonucleotides that had the same sequence
as the ﬁrst 20 or 100bp from the 50 part of the long 400bp
30-tailed template, respectively.
Other procedures
Other procedures including: identiﬁcation of RNAs
co-puriﬁed with the TEFM complex, assessing steady-
state levels of mtRNAs and mtDNA copy number by
quantitative PCR and measuring of the stability of mito-
chondrial transcripts are described in Supplementary data.
RESULTS
In silico identiﬁcation and domains of TEFM
We initially identiﬁed the c17orf42 gene, hereafter TEFM,
as a putative human mitochondrial Holliday Junction
Resolvase (HJR), as it exhibits signiﬁcant sequence
homology with the well-characterized bacterial HJR
RuvC (14) (Supplementary text and Supplementary
Figure S1). However, this hypothesis was not supported
by experiment, as recombinant TEFM isolated from
human mitochondria or puriﬁed from E. coli lacked any
detectable HJR activity (data not shown). In addition to
the RuvC-like RNase H fold TEFM contains two
tandemly repeated helix-hairpin-helix (HhH) motifs that
share sequence homology with the HhH motifs of bacter-
ial TEX protein, which functions in a variety of transcrip-
tional processes, and nuclear transcription elongation
regulator Spt6 (Figure 1A) (20). Like TEFM, both Spt6
and TEX contain an RNase H fold, although its pos-
ition in the protein differs in relation to the HhH motif
(Figure 1A, blue boxes). The RNase H fold of Spt6 and
TEX belongs to the YqgF family (21) and preserves the
overall topology and the structural elements of the same
fold of RuvC HJRs; however there are no reports of YqgF
functioning as a HJR (22,23).
TEFM is a mitochondrial protein
We analysed the sequence of the human TEFM protein
with several computer programmes that scan the
N-terminal region of proteins for the presence of a
putative MTS. Most of the algorithms used returned a
high probability of a MTS in TEFM (MultiLoc, 95.0%;
MitoProt II, 92.4%; TargetP, 78.2%; PSORT II, 51.2%).
In order to determine by experiment the cellular location
of TEFM, HOS cells were disrupted and fractionated.
The endogenous TEFM protein was concentrated in the
mitochondrial fraction similarly to well-characterized
mitochondrial matrix protein TFAM and the mitochon-
drial outer membrane TOM22 (Figure 1B). In a parallel
experiment, a haemagglutinin (HA) tagged version of the
protein (TEFM.HA) was transiently expressed in human
A549 adenocarcinoma cells; immunocytochemistry using
an anti-HA antibody and staining with the mitochondrial
probe (Mitotracker Red CMXRos) indicated that TEFM
was targeted to mitochondria, as the HA tagged protein
was distributed in a punctate pattern within mitochondria
(Figure 1C, arrow heads). Therefore, it is concluded that
TEFMproteinispresentinsidethemitochondriaofhuman
cells.
TEFM is necessary for OXPHOS function
In order to test experimentally the role of TEFM in
OXPHOS function, the expression of the gene was
inactivated by RNA interference. We identiﬁed two
siRNAs that efﬁciently depleted the target mRNA
(Supplementary Figure S2A) and protein (Figure 2A).
We inactivated TEFM in HOS cells and analysed
steady-state levels of respiratory chain subunits, as
OXPHOS dysfunction is often associated with aberrant
assembly or instability of mitochondrial respiratory
complexes. TEFM RNAi markedly reduced the abun-
dance of the complex IV subunit, COX2, and to a lesser
extent, NDUFB8, a component of complex I (Figure 2A).
The decreases in respiratory chain components were
accompanied by reduced cellular OCR by  50%
(Figure 2B) and uncoupling of the respiratory chain and
ATP synthase based on the respiratory control ratio
(Figure 2C). These results indicated that TEFM plays a
key role in mitochondrial energy production and given its
homology to nucleic acids modifying proteins (Figure 1A)
this was most likely to occur via a contribution to mtDNA
maintenance or expression.
TEFM gene silencing lowers the abundance of
promoter-distal mitochondrial transcripts
Inactivation of TEFM had little effect on mtDNA copy
number (Figure 3A) or mitochondrial replication inter-
mediates (data not shown) in HOS cells. Next,
Nucleic Acids Research, 2011,Vol.39, No. 10 4289mitochondrial transcripts were extracted from HOS cells
after TEFM RNAi. Quantiﬁcation of the steady-state
levels of mRNAs and rRNAs generated by transcription
from HSP and LSPof mtDNA revealed marked reductions
in many mitochondrial transcripts of cells subjected to
TEFM RNAi (Figure 3B–E). There was a clear pattern
to the changes in transcript levels: transcripts at
promoter-distal locations on the H-strand polycistronic
transcript were much less abundant than transcripts
mapping closer to the promoter, with the exception of
ND1 and ND2 mRNAs (Figure 3C–D). The exceptions
could be explained by changes in transcript stability, as
the half-life of ND1 was markedly increased in the
TEFM silenced cells (Supplementary Figure S2B).
Up-regulation of the steady-state level of ND1 mRNA
has been observed previously in cells with inactivated
genes that play a role in mitochondrial transcription and/
or processing (24). RNA19, which contains 16S rRNA,
tRNA-Leu
UUR and ND1, followed the general trend of
the other transcripts (Figure 3C and D, red). There was
no detectable increase in any precursor RNA in northern
blots (Supplementary Figure S3) and so the changes
in mitochondrial mRNAs levels were not attributable to
perturbed RNA processing.
In addition, we measured the abundance of several
mitochondrial tRNAs (mt-tRNA) encoded on the
H- and L-strands, from cells treated with TEFM-
targeted dsRNAs (Figure 4A–B). As with mitochondrial
mRNAs and rRNAs, TEFM gene-silencing decreased the
steady-state level of promoter-distal tRNAs encoded both
on H- and L-strand to a greater extent than promoter-
proximal tRNAs (Figure 4C–F). The steady-state levels
of mt-tRNAs that map in the last third of the mito-
chondrial genome (with respect to the promoter) were
decreased by  90% (e.g. tRNA-Ser
AGY or tRNA-Thr)
in cells treated with TEFM siRNA for 6 days. The effect-
ive loss of 90% tRNAs due to pathological mutation has a
substantial effect on complex I activity and mitochondrial
translation (Dunbar et al., 1996), and so the decrease in
mt-tRNAs caused by TEFM siRNA can explain the
associated severe decreases in OCR and mitochondrially
encoded respiratory chain components (Figure 2A). In
vertebrates mitochondria, transcription from the HSP
and LSP promoters produces polycistronic precursor
RNAs that are processed to yield the individual
mRNAs, tRNAs and rRNAs, and so reduced processivity
of POLRMT is the most straightforward explanation
for the larger decreases in the levels of promoter-distal
RNAs than promoter-proximal RNAs. Thus, the data
are consistent with the hypothesis of TEFM enhancing
transcription processivity of both stands of mtDNA.
TEFM interacts with the mitochondrial RNA polymerase
and other mitochondrial proteins with presumed roles in
RNA metabolism
In order to identify mitochondrial proteins that interact
with TEFM a FLAG- and STREP2-tagged version of
TEFM (TEFM.STREP2) was introduced into Flp-In
T-Rex
TM HEK 293T cells. The STREP2 binding group
was used in order to purify TEFM and potential interact-
ing proteins via a streptavidin-coated matrix after induc-
tion of the transgene for 24h with 20ng/ml of doxycycline
(Figure 5A). Streptavidin immobilized proteins from mito-
chondrial lysates of HEK cells expressing TEFM.STREP2
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Figure 2. Defects in respiratory chain function upon TEFM gene
silencing. (A) Western blot analyses of steady-state protein level of
TEFM and subunits of respiratory chain complexes in control cells
(untransfected cells and siRNA GFP) and cells treated with siRNA
TEFM for 3 and 6 days. (B) Oxygen consumption rate (OCR)
measured in quadruplicate population of control cells transfected
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(siRNA 1 in dark blue and siRNA 2 in light blue) and cells lacking
mtDNA (Rho0, yellow). (C) Respiratory control ratio (RCR) in cells
treated with siRNA GFP or siRNA TEFM for 3 or 6 days.
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Figure 3. Steady-state levels of mtDNA and mitochondrial transcripts in cells with inactivated TEFM. (A) mtDNA copy number as measured by
comparative qPCR of the mitochondrial Cox2 gene and single copy nuclear gene (APP) in controls (Untransfected and siRNA GFP) and cells
treated with TEFM siRNA (siRNA TEFM 1 and 2). *P<0.05, n=3, error bars indicate 1 SD. (B) Northern blot analyses of mitochondrial
transcripts transcribed from the HSP1 or LSP promoter in control cells (untransfected and treated with GFP siRNA) and cells treated with TEFM
siRNA for 3 or 6 days. Nuclear 28S rRNA was used as a loading control. (C and D) Quantiﬁcation of steady-state levels of the H-strand
mitochondrial transcripts in cells treated with TEFM siRNA for 3 days (C) and 6 days (D) analysed by northern blots. The values of the
relative RNA level (mtRNA/28S rRNA) were obtained by quantifying PhosphoImager scans of blots in the ImageQuant software and normalized
for the values obtained for control cells transfected with siRNA GFP. The relative RNA level of each transcript for siRNA TEFM 1 (square) and 2
(triangle) was plotted in the function of the distance of its 30 end from HSP. Dotted line, trend for siRNA GFP control; solid line, trend for siRNA
TEFM 1; dashed line, trend for siRNA TEFM 2. Red symbols indicate the RNA19 transcript. n=3, error bars=1 SD. The P-values (two-tailed
Student’s t-test) for each transcript calculated for combined values for both TEFM siRNAs for 3 days: 12S=0.103, 16S=0.719, RNA19=0.124,
ND1=0.492, ND2=0.234, COI=0.009, COII=0.031, ATP6/8=0.064, COIII=0.023, ND3=0.890, ND4/4L=0.006, ND5=0.007,
CytB<0.001, ND6=0.502; and for 6 days: 12S=0.813, 16S=0.092, RNA19=0.187, ND1=0.026, ND2=0.285, COI=0.003, COII=0.129,
ATP6/8=0.025, COIII=0.027, ND3=0.169, ND4/4L<0.001, ND5=0.002, CytB<0.001, ND6=0.137. The quantiﬁcation of the steady-state
level of the ND6 transcript that is transcribed from LSP is shown in Supplementary Figure S2.
Nucleic Acids Research, 2011,Vol.39, No. 10 4291or control cells were analysed by mass spectrometry. Three
mitochondrial proteins were identiﬁed consistently
in TEFM.STREP2 expressing mitochondrial lysates:
mitochondrial RNA polymerase—POLRMT (25),
Pentatricopeptide repeat domain 3—PTCD3 (26) and a
putative DEAH-box RNA helicase—DHX30 (27)
(Figure 5B). The mass spectrometry analysis also revealed
a variable set of mitochondrial ribosomal proteins
co-purifying with TEFM (Supplementary Table S2).
The co-puriﬁcation of POLRMT, DHX30 and PTCD3
with TEFM was conﬁrmed by immunoblotting
(Figure 5B). In contrast to these three proteins, highly
abundant mitochondrial proteins such as voltage-
dependent anion channel 1, VDAC-1 and cytochrome c
oxidase subunit II, Cox2 were depleted during the puriﬁ-
cation procedure (Figure 5D). Nor was there any appre-
ciable enrichment of known proteins of the mitochondrial
transcription initiation machinery (TFAM or TFB2M)
in our preparations of tagged TEFM (Figure 5E). Thus,
a substantial enrichment of a speciﬁc subset of mito-
chondrial proteins had been achieved by the afﬁnity
puriﬁcation procedure.
A B
D
C
F
E
Figure 4. Steady-state levels of mitochondrial tRNAs in TEFM-depleted cells. (A)–(B) Northern blot analyses of mitochondrial tRNAs transcribed
from the HSP (A) or LSP (B) promoter in control cells (untransfected and treated with GFP siRNA) and cells treated with TEFM siRNA for 3 or
6 days. Nuclear 18S rRNA was used as a loading control. (C)–(F) Quantiﬁcation of steady-state levels of the H-strand (C and D) or L-strand (E and
F) mitochondrial tRNAs in cells treated with TEFM siRNA for 3 days (C and E) and 6 days (D and F) analysed by Northern blots. The values of
the relative RNA level (tRNA/28S rRNA) were obtained by quantifying PhosphoImager scans of blots in the ImageQuant software and normalized
for the values obtained for control cells transfected with siRNA GFP. The relative RNA level of each tRNA for siRNA TEFM 1 (square) and 2
(triangle) was plotted in the function of the distance of its 30-end from the promoters. Dotted line, trend for siRNA GFP control; solid line, trend for
siRNA TEFM 1; dashed line, trend for siRNA TEFM 2. n=3, error bars=1 SD. The P-values (two-tailed Student’s t-test) for each tRNA
calculated for combined values for both TEFM siRNAs for 3 days: F=0.553, L(UUA/G)=0.303, , K=0.002, S(AGY)=0.001, T=0.002 ,
P=0.103, S(UCN)=0.004, Q<0.001; and for 6 days: F=0.656, L(UUA/G)=0.154, K<0.001, S(AGY)<0.001, T=0.002, P=0.297,
S(UCN)=0.002, Q=0.004.
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Figure 5. Mitochondrial RNA polymerase co-puriﬁes with TEFM. (A) A SDS–PAGE gel stained with Coomassie Brilliant Blue showing the protein
proﬁle of the afﬁnity puriﬁcation of the TEFM.STREP2 from the mitochondria of HEK cells. The most intense protein band of  40kDa seen in the
elution fractions 2–4 corresponds to the puriﬁed TEFM.STREP2 protein. M, total mitochondrial lysate; FT, ﬂow-through; MW, Molecular weight
marker. (B) A SDS–PAGE gel stained with Coomassie Brilliant Blue with concentrated fractions from 2 to 5 (E2–5). Protein bands were cut from the
gel and analysed by mass spectrometry. The identities of the protein are shown on the left-hand side. Some endogenous mitochondrial biotinylated
(continued)
Nucleic Acids Research, 2011,Vol.39, No. 10 4293In the reciprocal experiment, a tagged version of
POLRMT that carried a FLAG and a STREP2 binding
group (POLRMT.STREP2) was expressed in HEK cells.
POLRMT.STREP2 and interacting proteins were puriﬁed
on a streptavidin column as described above for TEFM
.STREP2 (Figure 5F). The TEFM protein co-puriﬁed
with POLRMT.STREP2 as conﬁrmed by western blot
(Figure 5G). Importantly, there was twice and ﬁve times
as much of TEFM present in the POLRMT.STREP2 peak
elution fractions compared to the known transcription
initiation factors: TFAM and TFB2M, respectively
(Figure 5H). These results suggest a tight association
between TEFM and POLRMT in human mitochondria.
TEFM is found in complexes containing RNA
Fractionation of afﬁnity-puriﬁed TEFM on blue native
gels revealed several complexes, the largest of which had
a molecular mass in excess of one mega-dalton
(Supplementary Figure S4A). This complex contained a
fraction of POLRMT and most of the PTCD3 co-purify-
ing with TEFM (Supplementary Figure S4A). Treatment
of the mitochondrial lysate with RNase A, but not DNase
I, disrupted the complex suggesting that RNA forms part
of the complex (Supplementary Figure S4B).
In order to determine which mitochondrial transcripts
were present in the TEFM complex, RNA was extracted
from the complex, radioactively labelled and hybridized
with immobilized fragments of human mtDNA
(SupplementaryFigureS4C).Allmitochondrialtranscripts
co-puriﬁed with TEFM, with rRNAs being the most
abundant(SupplementaryFigure S4C–D).The enrichment
of rRNAs associated with TEFM reﬂects their natural
overabundance (28).
The contribution of RNA to the interaction between
TEFM and POLRMT, DHX30 and PTCD3 was
investigated further, by screening mitochondrial lysates
of TEFM.STREP2 expressing cells that had, or had not,
been treated with nucleases, prior to loading the lysate on
a STREP2-afﬁnity column (Figure 6A). After RNase A
treatment neither PTCD3 nor DHX30 co-puriﬁed with
TEFM, whereas the association with POLRMT persisted.
DNase I had no effect on the proteins co-purifying with
TEFM (Figure 6B), which suggests PTCD3 and DHX30
are held in a complex with TEFM by RNA.
In our immunoﬂuorescence studies TEFM was
distributed in a punctate pattern within mitochondria.
Such a pattern is reminiscent of proteins found in the
mitochondrial nucleoid or newly synthesized mtRNA
(29). Because RNA is present in a complex containing
TEFM, and it interacts with POLRMT, we examined
the distribution of newly synthesized RNA, DNA and a
HA tagged version of TEFM in human cultured cells.
Mitochondrial RNA was visualized by growing A549
adenocarcinoma cells in the presence of bromouridine
(BrU) for 30min and applying a speciﬁc monoclonal
antibody to BrU-containing RNA. Some nucleoids
lacked both RNA and TEFM, whereas nucleoids with
newly synthesized RNA generally had TEFM.HA
present (Figure 6C), suggesting that TEFM is a compo-
nent of transcriptionally active nucleoids.
TEFM interacts with the catalytic domain of POLRMT
Human POLRMT displays signiﬁcant homology to the
RNA polymerase of T-odd bacteriophages, such as T7
(25,30). However, mitochondrial RNA polymerases
contain N-terminal extensions not present in the T7 poly-
merase (T7RNAP) (Figure 7A) and so this was considered
to be a potential binding region for TEFM. In order to
map the region of human mitochondrial RNA polymerase
that binds to TEFM, pull-down experiments with
truncated variants of POLRMT were performed. Myc-
tagged truncated versions of POLRMT (Figure 7A) were
transiently expressed in HEK cells that simultaneously ex-
pressed TEFM, under the control of a doxycycline indu-
cible promoter. Control experiments showed that
full-length, Myc-tagged POLRMT could be pulled down
only if TEFM was induced (Figure 7B). The POLRMT
variant lacking residues 61–767 interacted with TEFM
(Figure 7C, left), whereas the C-terminally truncated
variant of POLRMT (lacking residues 802–1230) was no
longer able to form a complex with TEFM (Figure 7C,
right). Therefore, we concluded that TEFM interacts with
the catalytic region of POLRMT, suggesting that it might
be involved directly in the regulation of polymerization.
Recombinant TEFM enhances POLRMT processivity
Despite signiﬁcant sequence similarity between the T-odd
phage RNA polymerases and mitochondrial RNA poly-
merases, there are important functional differences
between the two types of enzyme. For example, unlike
the single-subunit T7 RNA polymerase, POLRMT
requires auxiliary factors to initiate transcription at
promoter sequences (7). Previous reports have also
shown that recombinant POLRMT is non-processive on
ssDNA templates, synthesizing only relatively short RNA
species of 25–75nt compared to the >500nt achieved by
Figure 5. Continued
proteins (e.g. 3-hydroxyacyl-CoA dehydrogenase a-subunit or hydroxyacyl dehydrogenase, subunit B) were detected in the analysis as afﬁnity
puriﬁcation system used here is based on the interaction between the STREP2 tag and engineered streptavidin (Strep-Tactin), which also binds
biotin. Only biotinylated proteins were detected in mock afﬁnity capture experiments performed on parental HEK cells (data not shown). The
presence of the mitochondrial chaperone protein, MTHSP75, in our preparation could well result from a mitochondrial stress response caused by
overexpression of TEFM (41). (C)–(E) Western blots conﬁrming the identity of the proteins that co-purify with TEFM that were detected by mass
spectrometry (C) or documenting that there was no enrichment of highly abundant mitochondrial proteins (D) or mitochondrial proteins involved in
the initiation of mtDNA transcription (E). (F) A SDS–PAGE gel stained with Coomassie Brilliant Blue showing the protein proﬁle of the afﬁnity
puriﬁcation of the POLRMT.STREP2 from the mitochondria of HEK cells. The most intense protein band of  140kDa seen in the elution fractions
3–4 corresponds to the puriﬁed POLRMT.STREP2 protein. M, total mitochondrial lysate; FT, ﬂow-through; MW, Molecular weight marker.
(G) Western blots illustrating the protein proﬁle of the afﬁnity puriﬁcation of the POLRMT.STREP2 from the mitochondria of HEK cells.
(H) Relative abundance of proteins that co-purify with POLRMT.STREP2. The values were obtained by quantifying PhosphoImager scans of
western blots from (G) in the ImageQuant software and normalized for the values obtained for the total mitochondrial lysate.
4294 Nucleic Acids Research, 2011,Vol.39, No. 10T7 RNA polymerase (19). By analogy with transcription
initiation, we hypothesized that POLRMT might require
additional factors to regulate its processivity. TEFs that
increase the processivity of RNA polymerases are known
to operate in bacteria and the nucleus [reviewed in (12)].
Moreover, animal mitochondria require a highly
processive RNA polymerase (complex) to produce
polycistronic transcripts of 15, 11 and 2.7 knt, from
which all mtDNA products derive. TEFM was adjudged
a plausible candidate for enhancing processivity, as it
interacts with the catalytic region of POLRMT, but does
not co-purify with the initiation factors TFAM or TFB2M
(see above).
To test the above hypothesis, recombinant GST.TEFM
protein was puriﬁed to homogeneity (Figure 8A,
Supplementary Figure S5 and ‘Materials and Methods’
section) and the polymerase activity of recombinant
POLRMT on ssDNA assayed in vitro, with or without
recombinant GST.TEFM. POLRMT incubated with
ssDNA in the presence of radiolabelled UTP yielded
short RNA fragments ( 25–75nt), and longer RNAs
when recombinant GST.TEFM was included in the
reaction mixture (Figure 8B and C). The highest concen-
tration of GST.TEFM tested (50 pM), revealed a >2-fold
increase in RNA products of 200 and 400nt in length,
compared to POLRMT transcripts synthesized without
TEFM (Figure 8C). In a further test, the promoter inde-
pendent activity of POLRMT was assayed for 5–20min
on short or long 30-tailed dsDNA of 20, 100 or 400bp,
with or without recombinant GST.TEFM (Figure 8D–F).
In 5min reactions containing the highest concentration of
GST.TEFM the ratio of 400:20nt product was 75%
higher than that of reactions lacking TEFM (Figure 8F).
Therefore, POLRMT in concert with TEFM needs less
time to make transcripts 400nt in length than POLRMT
alone; i.e. POLRMT processivity is enhanced by TEFM
in vitro.
DISCUSSION
We show here that the gene product of c17orf42, named
TEFM, is a human mitochondrial protein, which is im-
portant for the synthesis of polycistronic RNAs, from
which the full panoply of mature mitochondrial tran-
scripts is generated. Transcription of DNA is divided
into an initiation stage, entailing recruitment of tran-
scription factors, including an RNA polymerase, to a
promoter and the commencement of RNA synthesis;
and an elongation step, during which the RNA polymer-
ase travels along the DNA template synthesizing an
RNA transcript. Several nuclear accessory factors have
been identiﬁed that facilitate transcription elongation.
The mechanism may be direct, modulating RNA poly-
merase activity; or indirect, modifying chromatin
structure (12).
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Nucleic Acids Research, 2011,Vol.39, No. 10 4295TEFM is an accessory factor of mitochondrial RNA
polymerase that enhances its processivity
TEFM can be used to afﬁnity purify mitochondrial RNA
polymerase (POLRMT) (Figure 5) indicating a tight asso-
ciation between the two proteins. TEFM is deemed likely
to facilitate the elongation step of mitochondrial tran-
scription because: (i) TEFM gene-silencing lowers the
abundance of promoter-distal mitochondrial transcripts;
(ii) the protein co-localizes with newly synthesized
mtRNA; (iii) TEFM interacts with the catalytic domain
of POLRMT, but not the mitochondrial transcription ini-
tiation factors TFAM and TFB2M; and (iv) it stimulates
POLRMT processivity in vitro.
TEFM’s similarities with known TEFs also support its
assignment as a mitochondrial TEF (Figure 1A). In
addition to sequence homology, TEFM shares several
functional resemblances with Spt6 and TEX. Both Spt6
and TEX interact directly with RNA polymerse II (22,31);
and Spt6 stimulates transcription elongation by RNA
polymerase II in vitro (32). Taken together, the presence
of the characteristic HhH motif and the Ribonuclease H
fold in Spt6, Tex and TEFM and the functional parallels
between the three proteins point to a similar role in
transcription.
Interdependence of transcription and translation in
mitochondria
The putative TEFM complex, in addition to POLRMT,
contains all mitochondrial mRNAs and rRNAs, mito-
chondrial ribosomal proteins and two other proteins:
PTCD3 (pentatricopeptide repeat domain 3) and
DHX30 (a putative DEAD-box RNA helicase). The
presence of RNA is integral to the complex, as RNase A
treatment abolished TEFM association with DHX30 and
PTCD3; it remains to be determined whether the three
proteins bind RNA independently, or have direct
contacts with each other that are stabilized by RNA.
PTCD3 contains a pentatricopeptide repeat (PPR) and
was ﬁrst identiﬁed as an RNA-binding factor associated
with the mitochondrial ribosome (26) and a recent report
has suggested that PTCD3 is involved in mitochondrial
translation in human cells (33). The PPR proteins
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Figure 7. TEFM interacts with C-terminal, catalytic part of POLRMT. (A) Schematic representation of the myc-tagged POLRMT constructs used
to map the interaction with TEFM in comparison with the T7 phage RNA polymerase (T7RNAP). The N-terminal extension present in the
POLRMT (dark gray) is missing in the T7RNAP. f.l., full-length. (B) Western blot of the control pull-down experiment with mock (left) and
the full-length POLRMT (right) transfected HEK cells that inducibly express TEFM.STREP2. The blot was incubated with the antibodies indicated
to the right. T, total cell lysate; P, pulled-down material. The asterisk indicates a non-speciﬁc band. (C) Western blot of the pull-down experiment
with the POLRMT lacking the N-terminal extension (POLRMT MTS-768-1230, left) or the C-terminal catalytic part (POLRMT 1-801, right) with
TEFM.STREP2. The asterisk indicates a non-speciﬁc band.
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Figure 8. Stimulation of the POLRMT activity by TEFM. (A) Coomassie Brilliant Blue stained SDS–PAGE gel showing E. coli puriﬁed the
GST.TEFM protein fusion. MW, molecular weight marker. (B) The synthesis of
32P-labelled RNA by POLRMT (0.35pmol) on M13mp18(+)
ssDNA in the absence (lane2) and the presence of 1.0pmol (lane 4), 0.33pmol (lane 5) and 0.11pmol (lane 6) of GST.TEFM was performed as
described in ‘Materials and Methods’ section. The products were separated on a 5% UREA polyacrylamide gel and subjected to autoradiography.
(continued)
Nucleic Acids Research, 2011,Vol.39, No. 10 4297constitute one of the largest gene families in plants and the
majority of them are, or are at least predicted to be,
localized in mitochondria and chloroplasts where they
play a variety of roles in RNA metabolism, including
splicing, editing, regulation of transcript stability and
translation (34). The mitochondrial isoform of the
putative RNA helicase DHX30 was identiﬁed as a candi-
date nucleoid protein (27). Of note, DHX30 forms foci
within mitochondria that are juxtaposed rather than coin-
cident with mtDNA (27). It is therefore probable that
DHX30, like TEFM, co-localizes with mtRNA, especially
as they are both found in the same RNA-containing
complex (Figure 5). Moreover, DHX30 is a DEAH-box
helicase, and so was always likely to participate in RNA
metabolism; its purpose may be to prevent secondary
structure formation of RNA and thereby facilitate
ribosome loading in mitochondria.
The human mitochondrial ribosome recycling factor
(mtRRF) co-immunoprecipitates mitochondrial ribo-
somes and a large number of proteins involved in mito-
chondrial RNA and DNA metabolism, including
POLRMT, PTCD3 and DHX30 (35). In another report,
the mitoribosomal protein, MRPL12, was shown to
interact directly with POLRMT and stimulates its
activity in vitro (11). TEFM also interacts with the tran-
scription machinery (POLRMT) and protein synthesis
apparatus (mitochondrial ribosomal RNAs, MRPs and
PTCD3) of mitochondria and so provides further
evidence of a physical coupling of transcription, and trans-
lation in mammals, as previously proposed (11,36–39).
In summary, we propose the TEFM protein identiﬁed
here is a critical component of the transcription apparatus
of human mitochondria. Further studies of this protein
should provide new insights into regulatory mechanisms
of mitochondrial transcription. There are also other
areas of research that could beneﬁt from additional know-
ledge of TEFM as its coding gene, c17orf42, is located
within the region of 17q11 microdeletions that encompass
the NF1 gene. Deletions of this region cause 5–10% of
cases of neuroﬁbromatosis type 1 (OMIM 162200); the
remainder are associated with intergenic mutations in
the NF1 gene. The phenotype of neuroﬁbromatosis type
1 generated through 17q11 microdeletions differs from
that associated with intragenic NF1 mutations and
might be related to haplo-insufﬁciency of speciﬁc genes
within the deleted interval, such as TEFM.
SUPPLEMENTARY DATA
Supplementary data are available at NAR Online.
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